Calendar
Highlights of ASH®
Get a synopsis of the top hematology research presented
at the latest ASH Annual Meeting and learn how it can
help improve your patient management and care strategies at the 2016 Highlights of ASH. This is your chance
to evaluate your diagnostic techniques and therapeutic
approaches and discuss with leading hematology experts
and colleagues how new research and clinical updates can
be translated into new patient care strategies.
March 5–6, 2016
Brisbane, Australia
Beach in Natal, Brazil, with the Navarro bridge in the background
April 29–30, 2016
Natal, Brazil
March 9–12, 2016
American Academy of Hospice and
Palliative Medicine Annual Assembly
Chicago, Illinois
This educational event brings together physicians, nurses, and other health-care providers to share research,
clinical best practices, and practice-related guidance to
improve quality of life for patients and families facing
serious or life-threatening conditions.
March 31–April 2, 2016
National Comprehensive Cancer
Network Annual Conference
Hollywood, Florida
The theme of this year’s NCCN Annual Conference
is “Advancing the Standard of Cancer Care,” and
attendees will discuss the latest cancer therapies,
quality initiatives, and selected NCCN Clinical
Practice Guidelines in Oncology.
April 16–20, 2016
Lyophilized Powder for Solution for Intravenous Injection
ADVERSE REACTIONS
Brief Summary of Prescribing Information: Please see
package insert for full Prescribing Information.
Common adverse reactions observed in greater than 5% of
subjects in the clinical trial were development of inhibitors to
porcine factor VIII.
INDICATIONS AND USAGE
OBIZUR, Antihemophilic Factor (Recombinant), Porcine
Sequence, is a recombinant DNA derived, antihemophilic
factor indicated for the treatment of bleeding episodes in
adults with acquired hemophilia A.
Limitations of Use:
Clinical Trials Experi